Analyst Ranking
Top 35%
#1779 out of 5072 analysts
Average Return
+1.66%
Win Rate
42%19 out of 45
Risk vs Reward
Poor
Good

Uy Ear's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Arcutis Biotherapeutics IncARQT
+306.12%$3.43$13.93
2024-01-02 -
2024-12-31
Strong Buy
Arcutis Biotherapeutics IncARQT
+272.38%$3.91$14.56
2024-01-02 -
2025-01-02
Strong Buy
Cabaletta Bio IncCABA
+131.36%$8.10$18.74
2023-03-16 -
2024-03-15
Strong Buy
Arcutis Biotherapeutics IncARQT
+49.85%$13.22$19.81
2025-02-25 -
2025-10-22
Buy
Arcutis Biotherapeutics IncARQT
+47.19%$9.24$13.60
2024-05-14 -
2025-05-14
Strong Buy

Uy Ear Analyst Color

Get additional color on Uy Ear's coverage of popular stocks

Uy Ear's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Uniqure NvQURE
5Buy$60.00+0.15%Maintains
a month ago
Mbx Biosciences IncMBX
2Buy$56.00+278.89%Maintains
a month ago
Acadia Pharmaceuticals IncACAD
14Hold$24.00+12.20%Maintains
3 months ago
Sarepta Therapeutics IncSRPT
7Hold$14.00-37.69%Downgrades
3 months ago
Tectonic Therapeutic IncTECX
6Buy$85.00+380.23%Maintains
5 months ago
Arcutis Biotherapeutics IncARQT
13Buy$21.00+6.01%Maintains
8 months ago
Relmada Therapeutics IncRLMD
1Hold$1.00-53.27%Downgrades
a year ago
Alkermes PLCALKS
5Buy$40.00+28.66%Maintains
a year ago
Sage Therapeutics IncSAGE
2Hold$16.00N/AMaintains
a year ago
Cartesian Therapeutics IncRNAC
3Strong Buy$40.00N/AInitiates Coverage On
a year ago
Evolus IncEOLS
3Strong Buy$23.00N/AMaintains
2 years ago
Neurocrine Biosciences IncNBIX
9Hold$140.00N/AMaintains
2 years ago
Revance Therapeutics IncRVNC
1Strong Buy$16.00N/AMaintains
2 years ago
Johnson & JohnsonJNJ
1Strong Buy$40.00N/AMaintains
2 years ago
Satsuma Pharmaceuticals IncSTSA
1Hold$2.00N/AReiterates
3 years ago
Cabaletta Bio IncCABA
1Strong Buy$10.00N/AReiterates
3 years ago
Ocugen IncOCGN
2Strong Buy$3.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.